ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with revenue projections soaring to $4.3B by 2030. Read more here.

Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...

Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation t Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We ...

Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation t Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We ...

In a recent transaction, Sheena Jonathan, Co-Founder of Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, sold a significant amount of company ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona. The launch environment for pharmaceutical industry ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona. The launch environment for pharmaceutical industry ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

Researchers developed a pan-immune-inflammation–based nomogram to accurately predict overall survival (OS) and ...

More from ESC: the SCOFF trial and fasting before cardiac cath, MATTERHORN, humbling data with AI, plus a reflection on the work of being a patient are the topics John Mandrola, MD, covers this week.